ADC Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO ADC Therapeutics is Ameet Mallik, benoemd in May2022, heeft een ambtstermijn van 2.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.78M, bestaande uit 19.1% salaris en 80.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.03% van de aandelen van het bedrijf, ter waarde $ 2.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4 jaar.

Belangrijke informatie

Ameet Mallik

Algemeen directeur

US$3.8m

Totale compensatie

Percentage CEO-salaris	19.1%
Dienstverband CEO	2.5yrs
Eigendom CEO	1.0%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Jul 18

Limiting Concerns On ADC Therapeutics' Prospects

Jun 06

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

May 30

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

May 10

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

Analyse CEO-vergoeding

Hoe is Ameet Mallik's beloning veranderd ten opzichte van ADC Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$215m
Mar 31 2024	n/a	n/a	-US$227m
Dec 31 2023	US$4m	US$721k	-US$240m
Sep 30 2023	n/a	n/a	-US$182m
Jun 30 2023	n/a	n/a	-US$184m
Mar 31 2023	n/a	n/a	-US$200m
Dec 31 2022	US$11m	US$475k	-US$157m

Compensatie versus markt: De totale vergoeding ($USD 3.78M ) Ameet } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).

Compensatie versus inkomsten: De vergoeding van Ameet is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ameet Mallik (51 yo)

2.5yrs

Tenure

US$3,779,425

Compensatie

Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ameet Mallik	CEO & Director	2.5yrs	US$3.78m	1.03% $ 2.9m
Jose Carmona	Chief Financial Officer	1.9yrs	US$1.26m	0.22% $ 622.0k
Mohamed Zaki	Chief Medical Officer	1.8yrs	US$4.40m	0.24% $ 688.3k
Lisa Kallebo	Corporate Controller & Chief Accounting Officer	no data	geen gegevens	geen gegevens
Michael Mulkerrin	Chief Technical Operations Officer	2.8yrs	geen gegevens	geen gegevens
Patrick van Berkel	Chief Scientific Officer	2.8yrs	geen gegevens	geen gegevens
Amanda Hamilton	Investor Relations Officer	no data	geen gegevens	geen gegevens
Peter Graham	Secretary & Chief Legal Officer	2yrs	geen gegevens	geen gegevens
Eugenia Litz	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Kimberly Pope	Senior VP & Chief People Officer	4.3yrs	geen gegevens	geen gegevens
Kristen Harrington-Smith	Chief Commercial Officer	2yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ADCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ameet Mallik	CEO & Director	2.4yrs	US$3.78m	1.03% $ 2.9m
Michael Forer	Board Observer	1.4yrs	US$846.56k	geen gegevens
Peter Hug	Vice-Chairman & Lead Independent Director	5.4yrs	US$212.61k	0.15% $ 420.8k
Ron Squarer	Chairman of the Board	4.6yrs	US$526.73k	1.6% $ 4.6m
Jean-Pierre Bizzari	Independent Non-Executive Director	2.4yrs	US$197.81k	0.059% $ 167.9k
Tyrell Rivers	Independent Non-Executive Director	6.4yrs	geen gegevens	geen gegevens
Victor Sandor	Independent Non-Executive Director	4.6yrs	US$227.72k	0.074% $ 212.4k
Robert Azelby	Independent Director	1.4yrs	US$127.67k	0.024% $ 68.9k
Viviane Monges	Independent Non-Executive Director	3.4yrs	US$231.33k	0.098% $ 279.6k
Thomas Pfisterer	Non-Independent Director	8.1yrs	US$194.30k	0.18% $ 513.0k

4.0yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ADCT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

ADC Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO & Director recently sold US$133k worth of stock

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

High number of new directors

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

ADC Therapeutics SA Announces Executive Changes

Recent updates

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ADC Therapeutics SA has filed a Follow-on Equity Offering in the amount of $100 million.

ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Limiting Concerns On ADC Therapeutics' Prospects

ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues

Consensus EPS estimates upgraded to US$1.84 loss, revenue downgraded

CEO & Director recently sold US$133k worth of stock

Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $105 million.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

ADC Therapeutics SA has filed a Follow-on Equity Offering.

ADC Therapeutics SA, Annual General Meeting, Jun 13, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

New minor risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Price target increased by 19% to US$10.50

Price target increased by 12% to US$8.80

New major risk - Share price stability

Consensus revenue estimates fall by 11%

ADC Therapeutics SA Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs At the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics: Slowly Moving Toward Solvency

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 20%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ADC Therapeutics SA to Report Q2, 2023 Results on Aug 08, 2023

China National Medical Products Administration Accepts Biologics License Application and Grants Priority Review for ZYNLONTA for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA Announces Voluntary Pause in the Enrollment of New Patients in the Phase 2 LOTIS-9 Clinical Trial Evaluating ZYNLONTA

Now 31% undervalued after recent price drop

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

High number of new directors

Price target decreased by 18% to US$9.33

ADC Therapeutics SA Announces Evolution of Board of Directors

ADC Therapeutics SA Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA(R) in Relapsed/Refractory DLBCL

ADC Therapeutics: Maybe A 2024 Story

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target increased by 9.4% to US$12.40

Consensus revenue estimates decrease by 29%, EPS upgraded

ADC Therapeutics SA Announces Updated Results from LOTIS-2 Trial to Be Presented at the European Hematology Association 2023 Hybrid Congress

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA, Annual General Meeting, Jun 14, 2023

Price target increased by 8.5% to US$13.20

Price target increased by 7.4% to US$13.20

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Consensus revenue estimates fall by 16%

Price target decreased by 15% to US$11.14

Price target decreased by 8.5% to US$12.29

ADC Therapeutics SA has completed a Follow-on Equity Offering in the amount of $60 million.

ADC Therapeutics stock slips after pricing stock offering by seller

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

ADC Therapeutics SA Announces Executive Changes

ADC Therapeutics SA and Swedish Orphan Biovitrum AB Announce the European Commission Approval of Zynlonta® (Loncastuximab Tesirine)

ADC Therapeutics Sa Appoints Jose Carmona as Chief Financial Officer

Jose Carmona joins ADC Therapeutics as CFO

Price target decreased to US$14.17

High number of new directors

Price target decreased to US$14.83

Price target increased to US$19.20